PT-141 10mg

Description

PT-141 (bremelanotide) is a melanocortin-receptor agonist with clinical trials and approved indication-specific use in female sexual-health contexts.

What it is

PT-141 (bremelanotide) is a melanocortin-receptor agonist with randomized phase-3 evidence and indication-specific regulatory approval history.

Mechanism snapshot

• Acts on melanocortin receptor pathways involved in central desire signaling.
• Evaluated for clinically meaningful sexual-desire endpoint changes in defined populations.
• Studied for durability and tolerability over longer treatment intervals.

Research programs

• Phase-3 efficacy and endpoint-validation programs.
• Long-term extension studies for safety and persistence of effect.
• Post-approval evidence synthesis in indication-specific populations.

Limitations

• Generalization outside studied populations is inappropriate.
• Outcome relevance depends on endpoint definitions and baseline status.
• Adverse-effect profiles require context-specific risk assessment.

Selected references

• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials - PubMed 2019
• Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder - PubMed 2019
• Bremelanotide: First Approval - PubMed 2019
• Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With HSDD (NCT02333071) - ClinicalTrials.gov Status snapshot
• Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With HSDD (NCT02338960) - ClinicalTrials.gov Status snapshot

Ordering

Add this item to your cart, submit your shipping details at checkout, and wait for your order confirmation. Interac e-Transfer instructions are sent after the order request is received.